Investigators for the Prevention of Recurrent Venous Thromboembolism (PREVENT) study noted a significant reduction in the risk of recurrent deep-vein thromboembolism (DVT) and pulmonary embolism (PE) in study participants treated with low-intensity warfarin therapy (target International Normalized Ratio [INR], 1.5-2) compared to those taking placebo. The low-intensity warfarin regimen was so beneficial to patients that the National Heart, Lung, and Blood Institute terminated the study early.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
2 Clarke Drive
Cranbury, NJ 08512